Bristol-Myers Squibb BMY Reblozyl — Total Revenues

Other product segments

Similar metrics at other companies

AMGNBLINCYTO — Total revenues

$415M+12.2%

AMGNENBREL — Total revenues

$320M-37.3%

AMGNRepatha — Total revenues

$876M+33.5%

OGNBrenzys — Revenue

$20M+42.9%

SUPNQelbree — Total revenues

$77.84M+20.2%

AMGNRepatha — Total revenues

$754M+35.7%

Questions, answered.

What is Bristol-Myers Squibb's reblozyl — total revenues?

Bristol-Myers Squibb (BMY) reported reblozyl — total revenues of $735M in Q2 2026.

How has Bristol-Myers Squibb's reblozyl — total revenues changed year-over-year?

Bristol-Myers Squibb's reblozyl — total revenues increased by 29.4% year-over-year, from $568M to $735M.

What is the long-term trend for Bristol-Myers Squibb's reblozyl — total revenues?

Over 4 years (2021 to 2025), Bristol-Myers Squibb's reblozyl — total revenues has grown at a 43.4% compound annual growth rate (CAGR), from $551M to $2.33B.

What does reblozyl — total revenues mean?

This metric represents the total global net sales generated from the commercialization of Reblozyl, a therapeutic product used primarily for the treatment of anemia in patients with specific blood disorders. As a key growth driver in the company's hematology portfolio, this revenue stream reflects the drug's market adoption, clinical utility, and competitive positioning within the oncology and hematology therapeutic areas. Monitoring this figure provides insight into the commercial success of the company's specialized biologic assets and their contribution to overall top-line performance.